Navigation Links
Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-SMN Rx Data Presented at 2013 AAN Annual Meeting
Date:3/14/2013

CARLSBAD, Calif., March 14, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host an investor event and a live webcast on Thursday, March 21, 2013 at 7:30 a.m. Pacific Time to discuss the ISIS-SMNRx Phase 1 data presented at the 2013 American Academy of Neurology Annual Meeting.

Interested parties may register to attend the event in San Diego, CA, or access the webcast on the "Investors & Media" page at www.isispharm.com.  The webcast will remain posted on Isis' Web site for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets, including Europe.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis' strategic alliance with Biogen Idec, and the discovery, development, activity, therapeutic and commercial potential and safety of ISIS-SMNRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Selects ProspectoRx and Clinical Pharmacology
2. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
3. Salix Pharmaceuticals Commits $1.125M to AGA Research Foundation
4. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
5. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
6. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
7. Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx
8. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
9. N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
10. Inovio Pharmaceuticals Closes $15.1 Million Offering of Common Stock and Warrants
11. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 Cirujanos ... para ayudar a los médicos a compartir sus mejores ... a escala mundial. Profesionales médicos de Europa, África, ... han apuntado a la aplicación, que combina la transmisión ... entorno totalmente seguro. Educación   "Imagine ...
(Date:5/24/2016)... , May 24, 2016  Diana Russell suffers from ... organs from the inside out.  This disease has put ... on her children and grandchildren to leave her home.  ... Diana,s family cannot haul the wheelchair.  So if there ... car, and Diana is left to wait for the ...
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... CloudLIMS, joins an elite ... Life Sciences Tech Solution Providers list of 2016 by CIOReview. , In a deliberate ... Life Sciences Tech Solution Providers 2016 has been concluded with. The positioning is based ...
(Date:5/25/2016)... ... May 25, 2016 , ... Cheryl Bowker of Bowker Insurance Group ... Dick McKenna Good Hands Legacy Award. McKenna ran one of Allstate’s most successful agencies ... inspire all those who knew him. The award named for him is not given ...
(Date:5/25/2016)... ... May 25, 2016 , ... Afrimesure specializes in providing clients ... to food and HVAC facilities. Their knowledgeable staff also takes care of the ... applications, Afrimesure offers a variety of MadgeTech systems available for sterilization and temperature ...
(Date:5/25/2016)... ... May 25, 2016 , ... Conrad ... annual Medical and Prescription Drug survey , an employee benefits ... which was conducted in December 2015, indicates that employers are turning to consumer ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... For more than fifty years, we've suffered ... we changed our diets to conform to the latest nutritional advice – advice that was ... the NIH, more than 2 in 3 American adults are considered to be overweight and ...
Breaking Medicine News(10 mins):